The fat tissue is very dynamic , and as a result of hyperplasia , which is a consequence of the proliferation and differentiation of preadipocytes may contribute to the development of obesity. This process is regulated by a complex number of specific genes. Among them, certainly deserves attention PPARg receptor whose expression is noted particularly strong in adipose tissue . It is a key factor in the adipogenesis process and is responsible for the differentiation of preadipocytes into mature cells called adipocytes . In addition , it regulates lipid metabolism in adipose tissue . Many studies have shown that activation of PPARg receptors increases the uptake by adipocytes formed during lipolysis or circulating in the blood in excess of free fatty acids and facilitates their storage and / or beta- oxidation. Is invaluable role of PPARg in the fight against metabolic symptoms of type 2 diabetes caused by obesity . Administration of synthetic PPARg agonists of the thiazolidinedione (TZD ) individuals diagnosed with type 2 diabetes leads to changes in the expression of many genes involved in glucose and lipid metabolism in adipose tissue . Medicines in the TZD induce the expression of genes involved in the transmembrane transport of glucose, lipolysis , lipogenesis , lipid storage and mitochondrial fatty acid oxidation . Prolonged activation by TZD ​​PPARg contributes to change the size of adipocytes in favor of smaller , more sensitive to insulin. All of these biochemical processes in which PPARg receptor is involved in adipose tissue , demonstrate the crucial role of this receptor, frequently lipid sensor that protects muscle tissue and liver from the high levels of lipids and glucose .